Home
/
Cue Biopharma, Inc.
/
Financials
/
Quarterly
Cue Biopharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cue Biopharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.15M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$2.95M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$421.0K
May 12, 2025
Q3
2025
Sep 30, 2024
$3.34M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$2.66M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$1.72M
May 12, 2025
Q3
2024
Sep 30, 2023
$2.10M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$1.38M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$187.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$68.0K
Nov 3, 2023
Q2
2023
Jun 30, 2022
$26.0K
Aug 8, 2023
Q1
2023
Mar 31, 2022
$1.00M
May 9, 2023
Q3
2022
Sep 30, 2021
$2.40M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$2.74M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$1.55M
May 10, 2022
Q3
2021
Sep 30, 2020
$704.0K
Nov 9, 2021
Q2
2021
Jun 30, 2020
$1.08M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$900.0K
May 10, 2021
Q3
2020
Sep 30, 2019
$984.0K
Nov 9, 2020
Q2
2020
Jun 30, 2019
$1.06M
Aug 7, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.45M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($8.48M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($12.26M)
May 12, 2025
Q3
2025
Sep 30, 2024
($8.66M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($10.17M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($12.35M)
May 12, 2025
Q3
2024
Sep 30, 2023
($11.01M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($13.19M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($13.11M)
May 9, 2024
Q3
2023
Sep 30, 2022
($10.96M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($13.21M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($14.26M)
May 9, 2023
Q3
2022
Sep 30, 2021
($12.99M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($10.28M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($12.51M)
May 10, 2022
Q3
2021
Sep 30, 2020
($10.03M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($10.83M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($12.82M)
May 10, 2021
Q3
2019
Sep 30, 2019
($6.99M)
Nov 7, 2019
Q2
2019
Jun 30, 2019
($9.52M)
Aug 8, 2019
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.60M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($8.64M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($12.30M)
May 12, 2025
Q3
2025
Sep 30, 2024
($8.82M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($10.38M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($12.67M)
May 12, 2025
Q3
2024
Sep 30, 2023
($11.42M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($13.52M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($13.38M)
May 9, 2024
Q3
2023
Sep 30, 2022
($11.03M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($13.09M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($14.24M)
May 9, 2023
Q3
2022
Sep 30, 2021
($13.02M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($10.30M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($12.52M)
May 10, 2022
Q3
2021
Sep 30, 2020
($10.13M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($10.94M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($13.00M)
May 10, 2021
Q3
2020
Sep 30, 2019
($7.09M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($9.23M)
Aug 7, 2020